Alex­ion shoots for fast re­view of Soliris suc­ces­sor us­ing a PRV; San­doz wades in­to med­ical cannabis busi­ness

→ Anx­ious to get their Soliris suc­ces­sor to the FDA, Alex­ion $ALXN is us­ing one of its two pri­or­i­ty re­view vouch­ers to shave four months off the reg­u­la­to­ry process for ALXN1210. Hailed as the next stan­dard of care for the rare blood dis­or­der parox­ys­mal noc­tur­nal he­mo­glo­bin­uria, ALXN1210’s files come with da­ta show­ing it is non-in­fe­ri­or — though not ex­act­ly su­pe­ri­or — to the block­buster Soliris, while car­ry­ing an eas­i­er dos­ing sched­ule. Just weeks ago, the New Haven, CT-based biotech al­so high­light­ed suc­cess­ful switch­ing of Soliris pa­tients to the new drug. Now that the US ap­pli­ca­tion is in, the com­pa­ny will ready its pitch for the EU and Japan lat­er this year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER